Fertility Care Startup Insurance in India: Clinical Liability and Storage Risk

Indian fertility care has grown from a fragmented clinical niche to a venture-funded sub-sector during 2023 to 2026. By Q1 2026, the sector includes approximately 2,700 registered ART clinics across India under the Assisted Reproductive Technology (Regulation) Act 2021 national registry, with a venture-funded cohort of roughly 40 startups operating multi-city chains, asset-light digital platforms, or specialty gamete banks. Disclosed equity funding into the cohort crosses USD 280 million since 2023.

The sector's risk profile differs materially from general healthcare. Fertility procedures span outpatient consultation, hormone stimulation cycles, surgical retrieval (under anaesthesia), embryology laboratory work, embryo transfer, and long-term cryostorage of gametes and embryos. Each step creates distinct liability exposure. Adverse outcomes can include unsuccessful cycles (the modal outcome), procedure complications (ovarian hyperstimulation syndrome, surgical injury, anaesthesia events), embryology errors (mislabelling, mix-up, fertilisation failure), storage failures (cryogenic equipment failure, power outage, tank rupture), and outcomes that produce successful but contested pregnancies (parentage disputes, congenital condition allegations).

The regulatory environment has consolidated. The ART Act 2021 and the Surrogacy (Regulation) Act 2021 with the ART Rules 2022 and Surrogacy Rules 2022 establish a national registration system, define permissible procedures, restrict commercial surrogacy, mandate counselling and informed consent protocols, and require insurance arrangements for surrogate mothers and oocyte donors. Non-compliance attracts both regulatory action and civil exposure.

The insurance market has begun to differentiate fertility care from general clinical practice. Indian general insurers writing professional indemnity for medical practitioners now apply distinct rate categories for ART practice, with three product layers responding to the exposure: medical professional indemnity for the clinical practice, property and equipment cover including specific cryogenic asset cover, and statutory cover for surrogates and donors mandated by the 2021 Acts.

Medical professional indemnity (MPI) insurance covers the registered medical practitioner against third-party claims arising from professional negligence in clinical care. Indian general insurers write MPI under wordings filed with IRDAI, with rate categories tiered by specialty risk. ART practice has historically been bucketed with gynaecology; the 2025-2026 market has begun separating ART as a distinct higher-rate category.

Four exposure areas drive the rate differential.

First, the unsuccessful cycle expectation. ART procedures have an inherent success ceiling: Indian sector data shows live birth rates of 18 to 32 percent per cycle depending on patient age, with cumulative live birth rates across multiple cycles reaching 40 to 55 percent. Patients receiving thorough counselling and informed consent understand these probabilities, but a significant minority of unsuccessful outcomes still produces claims alleging that the clinic over-promised, mis-counselled, or selected an inappropriate protocol. MPI policies respond to these claims, with defence costs often exceeding indemnity payments.

Second, procedure complication exposure. Oocyte retrieval is performed under sedation or general anaesthesia with risks including bleeding, infection, and ovarian hyperstimulation syndrome (OHSS). Severe OHSS occurs in approximately 0.5 to 1.5 percent of stimulated cycles and can require hospitalisation. Procedural claims for complications follow standard surgical malpractice patterns.

Third, embryology error exposure. Embryology laboratory work involves identification, handling, and storage of gametes and embryos with extreme precision requirements. Errors including mislabelling, mix-up of gametes between patients, fertilisation of incorrect gametes, or implantation of incorrect embryos produce some of the highest-severity claims in the field. International precedent suggests settlements of USD 1 million to USD 10 million for embryology mix-up cases. Indian case law is less developed but the trajectory of settlement values is upward.

Fourth, pregnancy outcome claims. Successful pregnancies producing children with congenital conditions or genetic disorders sometimes produce claims alleging that pre-implantation genetic screening was inadequate, that informed consent did not capture the risk, or that the clinic failed to recommend appropriate testing.

MPI premium for ART practitioners at INR 1 crore limit per practitioner runs INR 1.2 lakh to INR 3 lakh annually for individual practitioner cover, against INR 50,000 to INR 1.2 lakh for general gynaecology. Clinic-level cover at INR 10 crore limit runs INR 12 lakh to INR 40 lakh annually depending on case volume, complexity mix, and claims history.

Gamete and embryo cryostorage is the single highest-severity loss exposure in fertility care. A storage tank failure that causes loss of stored material can affect dozens to hundreds of patients simultaneously, each with claims spanning failed reproductive plans, emotional distress, and in some cases inability to ever produce biological children where the lost material was the patient's only viable option.

Indian fertility startups typically operate either onsite cryostorage at clinic locations or dedicated central storage facilities serving multiple clinics. The asset value of the equipment is modest (a clinical liquid nitrogen tank costs INR 8 lakh to INR 25 lakh); the indemnity exposure for stored material is the order-of-magnitude larger consideration.

Three property and equipment covers respond.

Standard property all risks cover responds to physical damage of the tanks themselves from fire, water, mechanical damage, or other physical perils. Premium scales with equipment value and is modest in absolute terms.

Machinery breakdown cover responds to mechanical or electrical failure of refrigeration, monitoring, and cryogenic equipment. Indian insurers offer machinery breakdown as a standard engineering insurance product; the cover is essential for cryogenic operations where equipment failure can produce material loss within hours of detection.

Deterioration of stock cover (sometimes called frozen stock cover) responds to loss of stored biological material from equipment failure, power outage, tank rupture, or temperature excursion. This cover is the operationally important layer. Wordings vary materially across Indian insurers, with three issues requiring attention.

The valuation basis clause. Stored gametes and embryos are not goods in the conventional commercial sense. Valuation can be on a per-vial replacement cost basis (covering the cost of repeating a stimulation cycle and retrieval to produce replacement material, typically INR 1.5 lakh to INR 4 lakh per cycle), on an agreed-value basis pre-set at policy inception, or on an indemnity basis tied to direct cost. Patient-side claims for emotional distress, loss of reproductive opportunity, and consequential damages are not typically covered by this clause but flow to the MPI policy.

The detection and response timeline. Cryogenic loss may take hours to days to manifest after initial equipment failure. Wordings typically require notification within 24 to 48 hours of discovery, with longer claim development timelines for verification of which material was affected.

The concurrent loss aggregation clause. A single equipment failure affecting multiple patients generates multiple individual claims. Insurers may treat these as one event for retention and limit purposes, or as separate events. The wording outcome materially affects the deductible structure.

Premium for deterioration of stock cover at INR 5 crore aggregate limit runs INR 4 lakh to INR 15 lakh annually, with rate variation reflecting equipment quality, monitoring systems, backup power availability, and operating protocols.

The ART Act 2021 and the Surrogacy (Regulation) Act 2021 mandate specific insurance arrangements for surrogates and oocyte donors that the clinic or commissioning party must procure.

Surrogate insurance. The Surrogacy Act requires the commissioning couple or single intended parent (the latter restricted to widowed or divorced women aged 35 to 45) to obtain insurance for the surrogate covering the pregnancy and post-partum period of 36 months. The cover must address medical complications, post-delivery health management, and life cover during the pregnancy. The Surrogacy Rules 2022 specify minimum benefits including hospitalisation cover, life cover, and ongoing medical management. Premium for a surrogate insurance package compliant with the Rules typically runs INR 28,000 to INR 65,000 for the full coverage period, depending on age and medical profile.

Oocyte donor insurance. The ART Act and Rules require insurance for oocyte donors covering the stimulation cycle, retrieval procedure, and complications including OHSS treatment for up to 12 months post-donation. Premium runs INR 8,000 to INR 18,000 per donation cycle.

The clinic's compliance role is to ensure these covers are in place before procedure commencement, with documented certificates of insurance in the patient or donor file. Failure attracts regulatory action under the Acts and creates direct civil exposure if the surrogate or donor suffers an insured event without cover.

The insurance market for these covers has consolidated around specific insurer products. ICICI Lombard, HDFC Ergo, and Bajaj Allianz have filed compliant wordings. Clinic chains typically establish master arrangements with one or two insurers to streamline procurement.

A structural point that catches many startups: the surrogate and donor insurance is funded by the commissioning party or clinic but is not the clinic's own insurance asset. The cover protects the surrogate or donor; the clinic's own MPI and clinic-level liability are separate. Confusing these layers has caused several disputes during 2024-2025 where clinics assumed surrogate insurance would respond to clinic-side claims that it does not address.

Fertility care operates on highly sensitive personal data: medical history, genetic information, reproductive history, treatment outcomes, identity of donors and surrogates, and identifying information of intended parents. The Digital Personal Data Protection Act 2023 and the DPDP Rules 2025 classify health data as sensitive personal data requiring elevated consent, processing, and breach response standards.

Fertility startups face three data exposure categories.

Clinic patient records, including pre-treatment counselling notes, hormone protocols, procedure records, and outcomes. Breach exposure includes regulatory penalty under DPDP and civil liability under the Act's grievance mechanism.

Donor and surrogate records, including identity documentation that the ART Act 2021 requires to be maintained for 25 years post-procedure. The combination of sensitivity and long retention creates a substantial residual data risk profile.

Genetic information from pre-implantation genetic testing or carrier screening. Genetic data has particular sensitivity given downstream implications for the individual and for family members.

Cyber insurance is the responsive product. Indian insurers offer cyber wordings refreshed following the IRDAI Information Security Guidelines 2023, with sub-limits for regulatory defence, notification costs, credit monitoring (less relevant for health data), and forensic investigation. Wordings for healthcare-focused operations are increasingly available with healthcare-specific incident response panels.

Premium for cyber cover at INR 10 crore limit for a fertility clinic chain with 20,000 to 50,000 patient records runs INR 8 lakh to INR 22 lakh annually, with the loading over generic cyber reflecting the sensitivity of health data and the long retention requirement.

Insurance economics for fertility startups scale with clinic count, case volume, and stored-material inventory.

Seed (1 to 3 clinics, INR 3 crore to INR 15 crore annual revenue): MPI at clinic level INR 5 crore (INR 8 lakh to INR 25 lakh annually), per-practitioner cover at INR 1 crore for each ART specialist, property all risks for clinic assets, basic deterioration of stock cover at INR 1 crore (INR 1.5 lakh to INR 4 lakh), surrogate and donor compliance procurement, basic cyber at INR 5 crore (INR 4 lakh to INR 12 lakh), D&O at INR 5 crore (INR 1.5 lakh to INR 5 lakh). Total: INR 25 lakh to INR 75 lakh annually.

Series A (4 to 12 clinics, INR 15 crore to INR 60 crore annual revenue): Scale MPI to chain level at INR 25 crore aggregate (INR 35 lakh to INR 1.2 crore), increase deterioration of stock cover to INR 5 crore with concurrent loss aggregation negotiation (INR 5 lakh to INR 15 lakh), cyber to INR 25 crore with healthcare incident response (INR 18 lakh to INR 45 lakh), D&O to INR 25 crore (INR 6 lakh to INR 20 lakh), add general liability at INR 15 crore. Total: INR 1.2 crore to INR 3.5 crore annually.

Series B (15+ clinics, multi-city operations): Master MPI structure with state-wise schedules, central storage facility cover with dedicated property and engineering placements, cyber at INR 50 crore with DPDP regulatory defence sublimit elevation, D&O at INR 50 crore with Side A. Consider crime cover for billing fraud and embryology process integrity. Total: INR 3.5 crore to INR 10 crore annually.

Broker selection for fertility care is more specialised than for general healthcare. The right broker has direct relationships with healthcare-specialist underwriters at multiple Indian insurers, understanding of the ART and Surrogacy Acts, and engagement with the embryology and cryogenic technical issues that underwriters now probe at submission.

The submission file should include:

• Clinic schedule with addresses, ART Act registration numbers, embryology lab certifications, anaesthesia capability, and case volume by procedure type.
• Practitioner schedule for all ART specialists, embryologists, and consulting practitioners with MCI registration, post-graduate qualification dates, ART experience, and individual case volume.
• Equipment and storage schedule with cryogenic tank inventory, current stored material count, backup power arrangements, monitoring system specifications, and equipment maintenance contracts.
• Claims history for the past five years across MPI, property, and any DPDP-equivalent data complaints with root cause analysis.
• SOP compliance with the ART Act, Surrogacy Act, and respective Rules, including counselling protocols, informed consent templates, donor and surrogate registration, and 25-year record retention systems.
• Quality and accreditation including NABH accreditation status if applicable, internal audit cycles, and embryology external quality assurance participation.

Underwriters cross-reference against the National Registry under the ART Act, NABH accreditation databases, and any pending complaints with state medical councils. Submission inconsistencies are penalised at quotation.

A cluster of brokers with active fertility care practice has emerged in Mumbai, Bengaluru, and Delhi, comprising both the global composites (Marsh, Aon, WTW, Gallagher) and Indian specialty healthcare brokers. Generic SME brokers are typically not equipped for fertility-specific wording work and should be avoided for this class.